WS #15828
In corporate news, Bristol Myers Squibb reported that its experimental cancer drug RYZ101 significantly slowed tumor progression in Phase 3 trials, a positive catalyst for the biotech sector. Galderma agreed to acquire ZO Skin Health for $1.5 billion, signaling consolidation in the skincare space. Conversely, Morgan Stanley reported falling profits amid a Wall Street slowdown, highlighting the pressure on financial institutions from reduced trading volumes and deal activity.
Biotech and Corporate Earnings
In corporate news, Bristol Myers Squibb reported that its experimental cancer drug RYZ101 significantly slowed tumor progression in Phase 3 trials, a positive catalyst for the biotech sector. Galderma agreed to acquire ZO Skin Health for $1.5 billion, signaling consolidation in the skincare space. Conversely, Morgan Stanley reported falling profits amid a Wall Street slowdown, highlighting the pressure on financial institutions from reduced trading volumes and deal activity.